Fig. 1: Cohort description and sampling timepoints. | npj Biofilms and Microbiomes

Fig. 1: Cohort description and sampling timepoints.

From: Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19

Fig. 1

Uninfected controls (C1–C15) and enrolled patients (P1–P30) classified by maximum OSCI score. We refer to scores between 1 and 4 as mild and scores between 5 and 8 as severe disease in further discussion. Sampling timepoints are represented according to the days after symptom onset for patients. For uninfected controls, sampling was performed two times, on day 1 and then again 3–7 days after the first sampling. The observation and hospitalization period is marked with a solid line, or a dashed black line when prolonged. Sample materials included oropharyngeal (OP) swabs, plasma, peripheral mononuclear blood cells (PBMCs), urine, stool, and tracheobronchial secretions (TBS). The use of antibiotics shortly before (i.e., recent abx) or during the sampling period (i.e., current abx) is marked for each participant. All control subjects were antibiotic-free for at least 3 months before and during the sampling period.

Back to article page